Microbix Biosystems Inc.
🇨🇦XTSE.MBXCanadaHealthcare
PriceCA$0.290.00 (0%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 7
- Medium: 7
- Low: 0
Debt to assets: a sudden drop below its trailing quarter average
Debt to equity: a sudden drop below its trailing quarter average
Gross profit margin: a sudden drop below its trailing quarter average
Long-term debt to equity: a sudden drop below its trailing quarter average
Net profit margin: a sudden drop below its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA59501P1045
- CUSIP
- 59501P104
Company
- Employees
- 0
- Headquarters
- Mississauga, Canada
- Website
- https://www.microbix.com
Market
- Shares outstanding
- 140.3M
- Market cap
- CA$40.68M
Highlights
- Market cap
- CA$40.68M
- EPS LTM
- -CA$0.00calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -125.22calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$21.13M-9.54%down year on year
- Net income
- -CA$324.83K-106.4%down year on year
- Gross margin
- 55.77%-2.52%down year on year
- Free cash flow
- -CA$270.79K-181.96%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Microbix Biosystems Inc. is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker MBX. Its market capitalisation is CA$40.68M, from 140.3M shares outstanding, as of . Across the 250 trading sessions to the shares traded between CA$0.21 and CA$0.33, and the last close of CA$0.29 sits 67% of the way up that range. The company is headquartered in Mississauga, Canada.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.